TG Therapeutics TGTX 深 滬
等待開盤 08-13 09:30:00 美东时间
27.12
+0.730
+2.77%
華盛通- 最 高27.12
- 今 開26.44
- 成交量 229.86万股
- 最 低 26.05
- 昨 收 26.39
- 總市值 43.12亿
- 52周最高 46.48
- 市盈率 靜 186.01
- 換手率 1.45%
- 52周最低 21.11
- 委 比 -92.47%
- 總股本 1.59亿
- 歷史最高 56.74
- 量 比 0.58
- 振 幅 4.05%
- 歷史最低 0.9563
- 每 手 1
- 風險率 6.05%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多TG Therapeutics files automatic mixed securities shelf
TG Therapeutics (NASDAQ:TGTX) filed automatic mixed securities shelf. Filing More on TG Therapeutics TG Therapeutics: Strong Execution Tempered By An Evolving Market TG Therapeutics falls after Q2 mis...
08-09 05:31
TG Therapeutics falls after Q2 miss despite guidance raise
TG Therapeutics (NASDAQ:TGTX) shares lost ~18% on Monday after the Morrisville, North Carolina-based biotech fell short of expectations with its Q2 2025 financials but raised its full-year sales outlo...
08-04 23:13
TG Therapeutics Raises FY2025 Sales Guidance from $575.000M to $585.000M vs $596.120M Est
TG Therapeutics (NASDAQ:TGTX) raises FY2025 sales outlook from $575.000 million to $585.000 million vs $596.120 million estimate.
08-04 19:01
Earnings Scheduled For August 4, 2025
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is likely to rep...
08-04 16:32
What's Next: TG Therapeutics's Earnings Preview
TG Therapeutics (NASDAQ:TGTX) is gearing up to announce its quarterly earnings ...
08-02 03:03
TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update
TG Therapeutics, Inc. has announced a conference call on August 4, 2025, at 8:30 AM ET to discuss second-quarter 2025 results and provide a business outlook. Michael S. Weiss, CEO, will主持会议，参与者可拨打1-877-407-8029（美国）或1-201-689-8029（国际）加入，会议名称为TG Therapeutics Earnings Call。网络直播和录音回放可在公司网站investors.tgtherapeutics.com上找到，录音将保留30天。TG Therapeutics专注于B细胞疾病治疗，已获得FDA批准的药物BRIUMVI®用于多发性硬化症治疗。如需更多信息，请访问www.tgtherapeutics.com，或联系投资者关系ir@tgtxinc.com（电话：1.877.57...
07-30 11:30
Cramer Backs This Mining Giant After $1.6B Bet
Jim Cramer recommends buying Rio Tinto due to its high yield. TG Therapeutics is also a buy, with strong first-quarter sales and potential for market share growth.
07-01 20:11
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
TG Therapeutics CEO Michael S. Weiss will participate in the Jefferies Global Healthcare Conference on June 3-5, 2025, in New York City. A fireside chat featuring Weiss is scheduled for June 4, 2025, at 12:50 PM ET, and will be available via live webcast on the company's Investors & Media page. TG Therapeutics is a biopharmaceutical company focused on developing treatments for B-cell diseases. The company's BRIUMVI® has received FDA approval for ...
06-02 12:00
Medical Properties Trust declares $0.08 dividend
Medical Properties Trust (NYSE:MPW) declares $0.08/share quarterly dividend, in line with previous. Forward yield 6.94% Payable July 17; for shareholders of record June 18; ex-div June 18. See MPW Div...
05-30 05:05
